Sanofi Consumer Healthcare India Limited reported a steady financial performance for the second quarter of FY26, posting a 7% year-on-year rise in revenue to ₹2,357 million, supported by robust domestic demand and improved profitability despite softer export sales. The company said domestic sales grew 12% during the quarter, driven by its product relaunch strategy, while export sales declined 9% due to a high base in the corresponding period last year. Profit Before Tax (PBT) increased 16% year-on-year to ₹919 million, reflecting stronger operational execution and disciplined cost management.
For the first half of FY26, Sanofi Consumer Healthcare India recorded revenue from operations of ₹4,649 million, up 18% from the year-ago period. Domestic sales rose 14%, aided by relaunch initiatives, while export sales climbed 27% on a low base. Profit Before Tax for the six-month period grew 25%, underscoring the company’s sustained momentum across key business segments. Commenting on the results, HimanshuBakshi, Managing Director, Sanofi Consumer Healthcare India Limited, said the quarter’s performance reflected disciplined execution across the business. He said targeted investments in brands and go-to-market capabilities had translated into profitable growth and market share gains across most of the company’s portfolio, reinforcing confidence in its long-term strategy.
In Kolkata, the company’s strong domestic growth is expected to support higher demand for its consumer healthcare portfolio across pharmacies, modern retail outlets and distribution channels in Kolkata and eastern India. Market participants believe continued investments in brand expansion and product relaunches could further strengthen Sanofi Consumer Healthcare India’s footprint in the region, where demand for over-the-counter healthcare products continues to grow.
